drug

SynKIR-310

Phase 1updated 3mo ago

by Verismo Therapeutics Inc

Phase 1

community read0 votes

indications

DLBCL

all catalysts(0)

nothing on the calendar yet

Trials studying SynKIR-310

phase1SynKIR-310 for Relapsed/Refractory B-NHLrecruitingn=36
—A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Productenrolling by invitationn=60

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 13m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

SynKIR-310

Phase 1updated 3mo ago

by Verismo Therapeutics Inc

Phase 1

community read0 votes

indications

DLBCL

all catalysts(0)

nothing on the calendar yet

Trials studying SynKIR-310

phase1SynKIR-310 for Relapsed/Refractory B-NHLrecruitingn=36
—A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Productenrolling by invitationn=60

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 13m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

SynKIR-310

indications

all catalysts(0)

Trials studying SynKIR-310

News(0)

Report a data issue

comments(0)

SynKIR-310

indications

all catalysts(0)

Trials studying SynKIR-310

News(0)

Report a data issue

comments(0)